Bronchial Asthma
Conditions
Interventions
Experimental group:Suhuang Zhike Capsules
Control group:Suhuang Zhike Capsule Placebo
Sponsors
Shanghai General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Outpatient chronic persistent patients who meet the typical asthma diagnostic criteria in the 2020 edition of the ''Guidelines for the Prevention and Treatment of Bronchial Asthma''; 2. The severity is classified as mild or moderate, and the ACT score is less than or equal to 19; 3. Aged 18 to 60 years; 4. Sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Combined use of compound methoxyphenamine capsules, codeine tablets, codeine oral solution, memin-pseudo-sesame solution, mephenol-pseudo-sesame tablets, compound licorice tablets, Jizhi syrup, Shedan Chuanbei Loquat Paste, Fresh Bamboo Oral Liquid, Qutanling Oral Liquid, Qutan Zhike Capsule, Feilike Mixture, Xuanfei Zhisou Mixture and other medicines containing cough-relieving ingredients, or Maxing cough tablets, Gecko Dingchuan pills and other traditional Chinese medicine preparations containing ephedra within 2 weeks; 2. Patients with a history of arrhythmia, coronary atherosclerotic heart disease, hypertension or hyperthyroidism and poor control; 3. Patients with severe heart, liver, kidney, brain, psychiatric, and neurological diseases; 4. Allergic to known drugs in this study; 5. Pregnant, lactating patients or those planning to become pregnant; 6. Those who have participated in or are participating in other clinical trials within 28 days; 7. Those who are considered unsuitable to participate in this trial by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ACT score; | — |
Secondary
| Measure | Time frame |
|---|---|
| LCQ score;AQLQ score;Lung function;Exploratory index;Clinical symptom score;Safety index; | — |
Countries
China
Contacts
Public ContactZhang Min
Shanghai General Hospital
Outcome results
None listed